Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.

Siddharth M PatelDavid A MorrowAndrea BellaviaDavid D BergDeepak L BhattPetr JarolimLawrence A LeiterDarren K McGuireItamar RazP Gabriel StegJohn P H WildingMarc S SabatineStephen D WiviottEugene BraunwaldBenjamin M SciricaErin A Bohula

Published in: European journal of heart failure (2023)

The risk of HHF varies across BMI categories for any given range of circulating NT-proBNP. These findings showcase the importance of considering BMI when applying NT-proBNP for heart failure risk stratification, particularly for patients with low-level elevations in NT-proBNP (125-<450 pg/ml) where there appears to be a clinically meaningful absolute and relative risk gradient.

Keyphrases

heart failure
body mass index
left ventricular
atrial fibrillation
weight gain
randomized controlled trial
cardiac resynchronization therapy
open label
study protocol